|
Each 1 ml contains:
Composition:
Etanercept
.......................................................................25
mg
Indications:
For reducing signs and symptoms and
inhibiting the progress of structural
damage in patients with moderately to
severely active rheumatoid arthritis. In
combination with methotrexate in
patients who do not respond to
methotrexate alone. To reduce symptoms
and signs of moderately to severely
active poly-articular-course juvenile
rheumatoid arthritis (JRA) in patients
who have had an inadequate response to
one or more DMARDs.
Description:
Etanercept inhibits TNF activity by
competitively binding to it and
preventing interactions with its cell
surface receptors. Elevated levels of
TNF have been found in psoriatic skin
lesions, and in synovial explants and
fluid from patients with psoriatic
arthritis.[5-7] Furthermore,
TNF levels in the serum of patients with
plaque psoriasis, and in blister fluids
of involved psoriatic skin[9]
have also been shown to be higher than
in those of controls. These values were
significantly correlated with the
psoriasis area and severity index (PASI)
scores, and TNF levels were reduced in
association with clinical resolution
after effective treatment.
The production of chemokines, and the
expression of adhesion molecules by
keratinocytes and vascular endothelial
cells can be stimulated by TNF produced
within psoriatic lesions. These signals
then cause recruitment of additional
inflammatory cells into the plaque.
Krueger suggests that TNF may function
as part of a positive feedback loop,
which acts to amplify and sustain the
inflammatory process within psoriatic
plaques.[10] Biologic
responses that are induced or regulated
by TNF are modulated by etanercept. It
may, therefore, serve to reduce
inflammation within plaques by breaking
this cycle.
Dosage:
Adults: 25mg given twice weekly as a
subcutaneous injection 72-96 hours
apart. Methotrexate, glucocorticoids,
NSAIDs, or analgesics may be continued
during treatment with etanercept. JRA
patients: For paediatric patients (4 to
17 years), dose is 0.4mg/kg (up to a
maximum of 25mg per dose) given twice
weekly as a subcutaneous injection 72-96
hours apart. Glucocorticoids, NSAIDs, or
analgesics may be continued during
treatment with etanercept.
Presentations:
Vial 1 ml
MRP Retailer Stockiest
9055.60 7244.00 6519.60 |
